SASkander Ben Ahmed

Skander Ben Ahmed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Skander Ben Ahmed has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandre Prat

    Neuroimmunology Research Lab, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, Canada

    1 shared publication
  • Antoine Fournier

    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)

    1 shared publication
  • Arsalan Haqqani

    National Research Council of Canada

    1 shared publication
  • Bettina Zierfuss

    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) / Université de Montréal

    1 shared publication
  • Camille Grasmuck

    Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR-CHUM) / Université de Montréal

    1 shared publication
  • Camille Sugère

    Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM) / Université de Montréal

    1 shared publication

Latest Publications

  • Open Access

    Mannose Receptor C type 2 influences autoimmune neuroinflammation and blood-brain barrier integrity

    by Bettina Zierfuss, Melanie Käch, Camille Sugère, Marion Morvan, Haritha Desu, Sandra Larouche, Skander Ben Ahmed, Wendy Klement, Karine Thai, Camille Grasmuck, et al.

    Relapses in Multiple Sclerosis (MS) are driven by pathogenic immune cells breaching the disrupted blood–brain barrier (BBB), leading to tissue damage and eventual disease progression1–3. Among the most effective therapies are those that block immune cell infiltration across the BBB, a multistep process involving activation, adhesion, rolling, transendothelial migration, and extracellular matrix (ECM) degradation. Current treatments broadly suppress the immune system and can cause adverse side effects4,5, highlighting the need for targeted approaches. Here, we identified a previously unrecognized role of ECM remodeling pathways and Mannose Receptor C-type 2 (MRC2) in invasive T lymphocytes as a potential therapeutic target. Typically low under physiological conditions, MRC2 was upregulated on T lymphocytes upon inflammatory stimulation in vitro, enriched in the periphery of MS patients during relapse and progressive disease, and present in cerebrospinal fluid and active brain lesions co-localized with Col IV, the major ECM component of the BBB. Genetic deletion of MRC2 impaired T lymphocyte-mediated Col IV degradation, adhesion, and transendothelial migration, and leading to reduced neuroinflammation in a sex-dependent manner in an MS-like mouse model. These findings suggest MRC2 as a key regulator of T lymphocyte infiltration into the CNS and a promising target for MS therapy.